Figure 3.

Telaprevir plus PEG‐IFN/RBV: overall SVR rates and SVR rates according to prior responses in treatment‐experienced subjects. The SVR rates were significantly higher for patients receiving telaprevir with or without a lead‐in phase. The SVR rates were not improved with a lead‐in phase. There was a gradient in the response, with the highest SVR rates achieved by relapsers and partial responders and the lowest rates achieved by null responders. T12PR48: telaprevir × 12 weeks, pegylated interferon and ribavirin × 48 weeks; LI means ‘lead‐in’ phase using pegylated interferon and ribavirin; SOC is ‘standard of care’ i.e., pegylated interferon and ribavirin.